Boston Scientific (NYSE:BSX) Earns Outperform Rating from Royal Bank Of Canada

Boston Scientific (NYSE:BSX)‘s stock had its “outperform” rating reissued by investment analysts at Royal Bank Of Canada in a research note issued on Monday,Benzinga reports. They presently have a $125.00 price target on the medical equipment provider’s stock. Royal Bank Of Canada’s price target would suggest a potential upside of 28.41% from the company’s current price.

Several other research firms have also recently weighed in on BSX. Barclays raised their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. BTIG Research reissued a “buy” rating and issued a $127.00 price target on shares of Boston Scientific in a report on Tuesday, September 23rd. Leerink Partnrs raised shares of Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a research report on Friday, September 19th. Finally, Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and an average price target of $118.38.

Boston Scientific Stock Down 0.9%

BSX opened at $97.34 on Monday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The stock has a market cap of $144.24 billion, a price-to-earnings ratio of 58.01, a PEG ratio of 2.36 and a beta of 0.65. Boston Scientific has a twelve month low of $80.64 and a twelve month high of $109.50. The company’s 50-day moving average price is $103.79 and its two-hundred day moving average price is $102.16.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company’s quarterly revenue was up 22.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts expect that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock valued at $18,397,457 over the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Boston Scientific

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Boston Scientific by 1.9% in the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares during the period. State Street Corp grew its stake in shares of Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after acquiring an additional 713,379 shares during the period. Geode Capital Management LLC grew its stake in shares of Boston Scientific by 2.0% in the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after acquiring an additional 622,602 shares during the period. Norges Bank bought a new stake in shares of Boston Scientific in the second quarter worth approximately $2,089,937,000. Finally, Invesco Ltd. grew its stake in shares of Boston Scientific by 1.4% in the second quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after acquiring an additional 226,578 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.